Drug General Information (ID: DDI210T3NC)
Drug Name			Pentamidine		Drug Info		Didanosine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antifungal Agents				Anti-Hiv Agents
Structure

Mechanism of Pentamidine-Didanosine Interaction (Severity Level: Major)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Pentamidine				Didanosine
Mechanism		Pancreatic toxicity				Pancreatic toxicity
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Pentamidine and Didanosine

Recommended Action
Management		The manufacturer recommends that the antiretroviral drugs should be interrupted, if clinically feasible, when treatment with intravenous pentamidine is initiated. If concomitant use cannot be avoided, patients should be closely monitored for clinical and laboratory signs of pancreatitis.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Hivid (zalcitabine). Roche Laboratories, Nutley, NJ.